DRAP approves Chinese diabetes medicine


The insulin glargine injecta BASAGINE developed by a Chinese pharmaceutical company received approval for registration by the Drug Regulatory Authority of Pakistan (DRAP), China Economic Net (CEN) reported it on Friday. According to the company, it is the first insulin glargine injection (prefilled injection pen) biosimilar drug in Pakistan,

Insulin glargine injection is an essential long-acting insulin analogue product in the treatment of diabetes for its efficacy and safety. In Pakistan, 33 million people aged 20-79 were living with diabetes in 2021, ranking third in the world after China and India. The prevalence of diabetes among adults aged 20-79 in Pakistan is 30.8%, the highest in the world, as per the latest data released by the International Diabetes Federation (IDF) Global Diabetes Overview 10th Edition (2021). It is learned that the overall market for insulin in Pakistan is over $50 million. Sanofi, Novo Nordisk and Eli Lilly have taken the majority of the market share in the country, and the Chinese product will bring more quality options to Pakistani patients.

“Since 2010, the pharmaceutical trade between China and Pakistan has maintained good momentum. As China eases its Covid restriction, we believe that this momentum will continue to strengthen”, the company’s public relation department told CEN in an interview. Meanwhile, according to CEN, Chinese patent medicine are listing in Pakistan promoting intensive collaboration

Lianhua Qingwen capsules, a Chinese patent medicine owned by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (stock code 002603), has obtained permission to be listed in Pakistan recently. This is the third Chinese patent medicine to be marketed in Pakistan after Tai Ji Huoxiang Zhengqi oral liquid and Jian Zhi syrup were licensed for sale and use in Pakistan. As a representative drug for the treatment of infectious diseases of respiratory system viruses, Lianhua Qingwen capsules have been included in the diagnosis and treatment protocols or guidelines for infectious public health events such as influenza A, influenza B and COVID-19 issued by China’s National Health Commission and the State Administration of Traditional Chinese Medicine for more than 30 times, and has shown unique value in the prevention and control of the epidemic worldwide.

The launch of Lianhua Qingwen in Pakistan is another overseas marketing license, following registration approval or import licenses in nearly 30 countries and regions including Canada, Thailand and Singapore.